Clinical Trial Update: Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial comparing Rituximab with Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in neuromyelitis optica spectrum disorder, with recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• Eculizumab (eculizumab)
• Inebilizumab (inebilizumab)
• Ravulizumab (ravulizumab)
• Rituximab (rituximab)
• Satralizumab (satralizumab)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: NMOSD | Phase 4 | Status: NOT_YET_RECRUITING